Development and Delivery Systems of mRNA Vaccines

被引：95
作者：
Liu, Tiancai [1 ]
Liang, Yongjun [1 ]
Huang, Liping [2 ]
机构：
[1] Southern Med Univ, Sch Lab Med & Biotechnol, Key Lab Antibody Engn Guangdong, Higher Educ Inst, Guangzhou, Peoples R China
[2] Nanfang Hosp, Obstet & Gynecol Ctr, Guangzhou, Peoples R China
来源：
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY | 2021年 / 9卷
基金：
中国国家自然科学基金;
关键词：
mRNA vaccine; molecular design; drug delivery; administration; COVID-19 mRNA vaccine; DIRECT GENE-TRANSFER; CTL RESPONSES; CELLS; NANOPARTICLES; VACCINATION; EXPRESSION; ELEMENTS; RAT; DNA;
D O I：
10.3389/fbioe.2021.718753
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Since the outbreak of SARS-CoV-2, mRNA vaccine development has undergone a tremendous drive within the pharmaceutical field. In recent years, great progress has been made into mRNA vaccine development, especially in individualized tumor vaccines. mRNA vaccines are a promising approach as the production process is simple, safety profiles are better than those of DNA vaccines, and mRNA-encoded antigens are readily expressed in cells. However, mRNA vaccines also possess some inherent limitations. While side effects such as allergy, renal failure, heart failure, and infarction remain a risk, the vaccine mRNA may also be degraded quickly after administration or cause cytokine storms. This is a substantial challenge for mRNA delivery. However, appropriate carriers can avoid degradation and enhance immune responses, effector presentation, biocompatibility and biosafety. To understand the development and research status of mRNA vaccines, this review focuses on analysis of molecular design, delivery systems and clinical trials of mRNA vaccines, thus highlighting the route for wider development and further clinical trials of mRNA vaccines.
引用
收藏
页数：10
相关论文
共 45 条
[1]  
ACSADI G, 1991, NEW BIOL, V3, P71
[2]   Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors [J].
Bahmani, Baharak ;
Gong, Hua ;
Luk, Brian T. ;
Haushalter, Kristofer J. ;
DeTeresa, Ethel ;
Previti, Mark ;
Zhou, Jiarong ;
Gao, Weiwei ;
Bui, Jack D. ;
Zhang, Liangfang ;
Fang, Ronnie H. ;
Zhang, Jie .
NATURE COMMUNICATIONS, 2021, 12 (01)
[3]   A VERSATILE VECTOR FOR GENE AND OLIGONUCLEOTIDE TRANSFER INTO CELLS IN CULTURE AND IN-VIVO - POLYETHYLENIMINE [J].
BOUSSIF, O ;
LEZOUALCH, F ;
ZANTA, MA ;
MERGNY, MD ;
SCHERMAN, D ;
DEMENEIX, B ;
BEHR, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (16) :7297-7301
[4]   Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN [J].
de Jong, Susan ;
Chikh, Ghania ;
Sekirov, Laura ;
Raney, Sam ;
Semple, Sean ;
Klimuk, Sandra ;
Yuan, Ning ;
Hope, Micheal ;
Cullis, Pieter ;
Tam, Ying .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (08) :1251-1264
[5]   Stability analysis of chemically modified mRNA using micropattern-based single-cell arrays [J].
Ferizi, Mehrije ;
Leonhardt, Carolin ;
Meggle, Christian ;
Aneja, Manish K. ;
Rudolph, Carsten ;
Plank, Christian ;
Raedler, Joachim O. .
LAB ON A CHIP, 2015, 15 (17) :3561-3571
[6]   Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes [J].
Gan, Li-Ming ;
Lagerstrom-Fermer, Maria ;
Carlsson, Leif G. ;
Arfvidsson, Cecilia ;
Egnell, Ann-Charlotte ;
Rudvik, Anna ;
Kjaer, Magnus ;
Collen, Anna ;
Thompson, James D. ;
Joyal, John ;
Chialda, Ligia ;
Koernicke, Thomas ;
Fuhr, Rainard ;
Chien, Kenneth R. ;
Fritsche-Danielson, Regina .
NATURE COMMUNICATIONS, 2019, 10 (1)
[7]   Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial [J].
Gandhi, Rajesh T. ;
Kwon, Douglas S. ;
Macklin, Eric A. ;
Shopis, Janet R. ;
McLean, Anna P. ;
McBrine, Nicole ;
Flynn, Theresa ;
Peter, Lauren ;
Sbrolla, Amy ;
Kaufmann, Daniel E. ;
Porichis, Filippos ;
Walker, Bruce D. ;
Bhardwaj, Nina ;
Barouch, Dan H. ;
Kavanagh, Daniel G. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 71 (03) :246-253
[8]   Control of translation initiation in animals [J].
Gray, NK ;
Wickens, M .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 1998, 14 :399-458
[9]  
Heiser A, 2002, J CLIN INVEST, V109, P409, DOI 10.1172/JCI14364
[10]   Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen [J].
Hess, PR ;
Boczkowski, D ;
Nair, SK ;
Snyder, D ;
Gilboa, E .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (06) :672-683
12345